217 related articles for article (PubMed ID: 25003957)
1. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
[TBL] [Abstract][Full Text] [Related]
2. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
[TBL] [Abstract][Full Text] [Related]
3. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
[TBL] [Abstract][Full Text] [Related]
4. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
[TBL] [Abstract][Full Text] [Related]
5. The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model.
Yang F; Wang Y; Zhang Z; Hsu B; Jabs EW; Elisseeff JH
Bone; 2008 Jul; 43(1):55-63. PubMed ID: 18407821
[TBL] [Abstract][Full Text] [Related]
6. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.
Mansukhani A; Bellosta P; Sahni M; Basilico C
J Cell Biol; 2000 Jun; 149(6):1297-308. PubMed ID: 10851026
[TBL] [Abstract][Full Text] [Related]
7. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
Wang Y; Sun M; Uhlhorn VL; Zhou X; Peter I; Martinez-Abadias N; Hill CA; Percival CJ; Richtsmeier JT; Huso DL; Jabs EW
BMC Dev Biol; 2010 Feb; 10():22. PubMed ID: 20175913
[TBL] [Abstract][Full Text] [Related]
8. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
9. Exosome-mediated small interfering RNA delivery inhibits aberrant osteoblast differentiation in Apert syndrome model mice.
Myo AC; Kobayashi Y; Niki Y; Kamimoto H; Moriyama K
Arch Oral Biol; 2023 Sep; 153():105753. PubMed ID: 37348363
[TBL] [Abstract][Full Text] [Related]
10. Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.
Holmes G; Basilico C
Dev Biol; 2012 Aug; 368(2):283-93. PubMed ID: 22664175
[TBL] [Abstract][Full Text] [Related]
11. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome.
Yeh E; Fanganiello RD; Sunaga DY; Zhou X; Holmes G; Rocha KM; Alonso N; Matushita H; Wang Y; Jabs EW; Passos-Bueno MR
PLoS One; 2013; 8(4):e60439. PubMed ID: 23593218
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling.
Miraoui H; Oudina K; Petite H; Tanimoto Y; Moriyama K; Marie PJ
J Biol Chem; 2009 Feb; 284(8):4897-904. PubMed ID: 19117954
[TBL] [Abstract][Full Text] [Related]
14. Craniofacial divergence by distinct prenatal growth patterns in Fgfr2 mutant mice.
Motch Perrine SM; Cole TM; Martínez-Abadías N; Aldridge K; Jabs EW; Richtsmeier JT
BMC Dev Biol; 2014 Feb; 14():8. PubMed ID: 24580805
[TBL] [Abstract][Full Text] [Related]
15. Inhibited Wnt signaling causes age-dependent abnormalities in the bone matrix mineralization in the Apert syndrome FGFR2(S252W/+) mice.
Zhang L; Chen P; Chen L; Weng T; Zhang S; Zhou X; Zhang B; Liu L
PLoS One; 2015; 10(2):e112716. PubMed ID: 25693202
[TBL] [Abstract][Full Text] [Related]
16. Dura in the pathogenesis of syndromic craniosynostosis: fibroblast growth factor receptor 2 mutations in dural cells promote osteogenic proliferation and differentiation of osteoblasts.
Ang BU; Spivak RM; Nah HD; Kirschner RE
J Craniofac Surg; 2010 Mar; 21(2):462-7. PubMed ID: 20489451
[TBL] [Abstract][Full Text] [Related]
17. Beyond the closed suture in apert syndrome mouse models: evidence of primary effects of FGFR2 signaling on facial shape at birth.
Martínez-Abadías N; Percival C; Aldridge K; Hill CA; Ryan T; Sirivunnabood S; Wang Y; Jabs EW; Richtsmeier JT
Dev Dyn; 2010 Nov; 239(11):3058-71. PubMed ID: 20842696
[TBL] [Abstract][Full Text] [Related]
18. Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis.
Miraoui H; Ringe J; Häupl T; Marie PJ
Hum Mol Genet; 2010 May; 19(9):1678-89. PubMed ID: 20124286
[TBL] [Abstract][Full Text] [Related]
19. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand.
Anderson J; Burns HD; Enriquez-Harris P; Wilkie AO; Heath JK
Hum Mol Genet; 1998 Sep; 7(9):1475-83. PubMed ID: 9700203
[TBL] [Abstract][Full Text] [Related]
20. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
